This HTML5 document contains 35 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n11http://linked.opendata.cz/resource/drugbank/drug/DB07091/identifier/pdb/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/drugbank/drug/DB07091/identifier/pubchem-compound/
n9http://linked.opendata.cz/resource/drugbank/drug/DB07091/identifier/pubchem-substance/
n10http://linked.opendata.cz/resource/drugbank/drug/DB07091/identifier/drugbank/
n13http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB07091
rdf:type
n3:Drug
n3:group
experimental
owl:sameAs
n8:DB07091 n13:DB07091
dcterms:title
(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexyloxy)ethanoyl)pyrrolidine-2-carboxamide
adms:identifier
n6:24963036 n9:99443562 n10:DB07091 n11:46U
n3:IUPAC-Name
n4:271B48EB-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B48F1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B48F0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B48ED-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B48EE-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B48EF-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B48E9-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B48E7-363D-11E5-9242-09173F13E4C5 n4:271B48EA-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B48E8-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B48F7-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B48F8-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B48F2-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B48F3-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B48F5-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B48F4-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B48F6-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B48FD-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B48FF-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4900-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B48FC-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B48FB-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B48FE-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B48EC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B48F9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B48FA-363D-11E5-9242-09173F13E4C5